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Introduction 
Uveal melanoma, as the most common primary intraocular tumor in adults, has a reported 
incidence of 5–7 cases per million of the population.[1] According to long-term survival 
studies, metastases develop in up to 50% of cases within 15 years of diagnosis.[2] Metastatic 
choroidal melanoma generally presents in the liver.[2,3,4] In most series, hepatic involvement 
is reported in up to 95% of patients, while 50% are noted to have coexisting extrahepatic 
metastases (lung, bone, and skin).[5] Historically, abdominal ultrasound has been used to 
stage patients with uveal melanoma because metastatic disease is usually first found in the 
liver. 
Whole-body positron-emission tomography/computed tomography (PET/CT) has been used 
for staging of systemic lymphoma, cutaneous melanoma, and gastrointestinal malignancies. 
PET was developed from the knowledge that cancer cells display-deregulated energetics that 
is linked to increased glucose consumption.[6] PET/computed tomography scanning uses 
radioactive glucose [18-fluoro-2-deoxyglucose (FDG)] that accumulates within neoplastic 
lesions that contain metabolically active cells.[7] The FDG injected patient is imaged on a 
whole-body PET scanner, the computed tomography portion of a PET/CT provides anatomic 
information about the location, size, and shape of tumors. Ultimately, the anatomic and 
metabolic findings are combined to provide information on function and location. 
Whole-body PET/CT imaging is gaining worldwide acceptance in the initial staging, 
screening and management of patients with cancer.[8,9] 
The objective of this study was to report the value of staging uveal melanoma with FDG-
PET/CT and abdominal ultrasound. 
Materials and Methods 
From January 2012, patients with primary uveal malignant melanoma over 4 mm in thickness 
were staged with 18-FDG) whole-body PET/CT (Phillips Gemini TF LS064) and abdominal 
ultrasound. 4 mm was selected as the cut off because this is the minimum resolution of the 
PET/CT scan. Tumors <4 mm in thickness were staged with abdominal ultrasound only but 
not included in this study. The imaging findings of each modality were compared in a 
retrospective case note analysis. We recorded the incidence of metastatic uveal melanoma at 
diagnosis and other incidental findings detected using both imaging techniques. We recorded 
the size, location and the international tumor, node, and metastasis (TNM) stage of each 
primary uveal melanoma. If abnormalities were noted on PET/CT scan or abdominal 
ultrasound, patients were further investigated with CT and magnetic resonance imaging 
(MRI) scans (with contrast) or liver biopsy to confirm the presence of metastatic disease. 
Positron emission tomography/computed tomography imaging 
Patients were instructed to refrain from eating a carbohydrate-based dinner the previous night 
and to fast 4–6 h before injection of 18-fluoro-2-deoxyglucose (FDG). These measures 
diminish physiological glucose utilization and reduce insulin serum levels to baseline. The 
full body PET/CT scan began at the top of the head and ended at the bottom of the feet. The 
CT portion consisted of a multi-detector helical CT scanner. The FDG was injected via an 
intravenous line followed by 10 ml of normal saline. The resolution of the PET scan was 4 
mm. The PET scan reconstructed the images and utilized the CT scan to correct for 
attenuation. Then workstation was used to fuse and display the PET and CT images and to 
produce the final image [Figure 1]. 
Positron emission tomography/computed tomography image evaluation 
The PET/CT images were studied for the presence of lymph node and distant metastases and 
were based on qualitative analysis. Data were evaluated for areas of focally increased glucose 
uptake and by maximally standardized uptake values (SUV). Glucose uptake above levels of 
the surrounding tissue qualitatively and an uptake value above 2.5 SUV quantitatively 
indicated malignancy. Distant disease was confirmed via biopsy or additional imaging. This 
study was approved by the Institutional Review Board and adhered to the tenets of The 
Declaration of Helsinki. 
Results 
Between January 2012 and January 2014, 108 patients underwent staging for primary uveal 
melanoma with whole-body FDG PET/CT and abdominal ultrasound. There were 10 anterior 
uveal melanomas, of which 7 were located in the ciliary body, one had iridociliary 
involvement and there were two ring melanomas. Of the remaining 98 tumors, 83 were 
choroidal and 15 had ciliochoroidal involvement. The mean tumor height was 7.9 mm while 
the mean tumor diameter was 13.1 mm[Table 1]. 
Using the collaborative ocular melanoma study group 
Classification, there were 5 small (4.6%), 46 medium (42.6%), and 57 large (52.7%) tumors. 
The TNM classification 7th edition of the American Joint Committee on Cancer (AJCC) 
Cancer Staging Manual 2009 was also used to categorize uveal melanoma [Table 1]. 
Three of 108 patients (2.7%) were found to have distant metastatic disease at staging. Two 
had posterior choroidal melanoma and one had a ciliary body melanoma. Two of the 3 
metastatic patients presented with large tumors based on the Collaborative Ocular Melanoma 
Study criteria and were treated with enucleation. The third case had a medium sized 
melanoma and was treated with plaque brachytherapy. All 3 patients had hepatic metastases, 
confirmed on biopsy in one case [Figure 2]. One of the three metastatic cases had additional 
extrahepatic widespread metastases in the lungs, lymph nodes, and bones seen on whole-body 
FDG PET/CT. 
The hepatic findings using abdominal ultrasound and PET/CT were consistent in one patient. 
In 2 of 3 patients with metastatic disease, the hepatic findings using abdominal ultrasound 
and PET/CT differed. In the first case, the abdominal ultrasound misdiagnosed metastatic 
disease as hepatic cysts; however, FDG PET/CT revealed several foci of intense metabolic 
activity in both lobes of the liver. In the second case, PET/CT missed the presence of hepatic 
metastases as no metabolic activity was detected, however a hypodense hepatic lesion was 
identified on abdominal ultrasound. An abdominal CT scan with contrast confirmed the 
presence of an enlarging hepatic metastasis. 
PET/CT identified second primary malignancies in 10 patients (9.3%). The second primary 
cancers were found in the lung, breast, colon, thyroid, and adrenal gland. All patients with a 
second cancer were referred to the appropriate multidisciplinary team for specialist treatment 
at St Bartholomew's Cancer Centre. Incidental extrahepatic pathology was found in another 
12 patients (11.1%). 
Coincidental benign liver findings, such as fatty liver, hepatic cysts or hemangiomata were 
seen in 20 patients (18.5%) using abdominal ultrasound. Whereas, whole-body PET/CT 
detected benign liver pathology in only 4 patients (3.7%) within the same cohort. 
Discussion 
The detection of metastatic uveal melanoma at diagnosis of the primary tumour is a rare 
event but has major prognostic implications. The median survival for stage IV disease in 
uveal melanoma is approximately 6–9 months with 80% of deaths occurring within the 
1st year of metastatic disease.[10] The UK National Guidelines for the management of Uveal 
Melanoma, published in the European Journal of Cancer, recommend staging uveal 
melanoma patients.[11] Although, the detection of distant metastases may not necessarily 
influence the management of the primary uveal melanoma.[11] The authors suggested that 
further research is required to determine the choice imaging modality.[11] 
There have been a few publications on the use of liver function tests and chest X-ray in 
staging patients with uveal melanoma.[11,12] It was concluded that these investigations have a 
high specificity but not a high sensitivity for the early detection of metastatic disease. Staging 
uveal melanoma patients with full-body PET/CT has been proposed to increase diagnostic 
accuracy.[13] PET/CT imaging has been used in the diagnosis, staging, and restaging of 
various cancers.[8,9,14] The combination of metabolic and structural information provided by 
the PET/CT has improved the accuracy of tumor staging, detection of recurrences and has a 
significant impact on patient management.[14] High sensitivity rates and the value of FDG-
PET for the detection of hepatic metastases from uveal melanoma have already been 
reported.[9,13,15] Klingenstein et al.[16] reported that PET/CT detected metastases from uveal 
melanoma in all of their patients. 
Ionizing imaging such as PET/CT is not recommended for surveillance of metastatic uveal 
melanoma due to the high radiation doses associated with this imaging modality.[11] In our 
study, we report the use of PET/CT as a staging tool only. All patients receive long-term 
surveillance every 6 months with non-ionizing imaging, namely abdominal MRI or 
ultrasound. 
Metastatic uveal melanoma 
In our series, only 3 (2.7%) uveal melanoma patients were found to have metastases at the 
time of diagnosis, this is consistent with the overall incidence of metastatic disease at 
diagnosis reported by other investigators.[13] In our study, PET/CT identified hepatic 
metastases in 2 of 3 patients (66.6%). In contrast, abdominal ultrasound identified hepatic 
abnormalities in all three patients. In two patients (66.6%), the liver ultrasound accurately 
detected hepatic metastases, in the third case metastatic deposits were misdiagnosed as 
hepatic cysts. Staging with PET/CT allowed the detection of extra-hepatic metastases this is 
important as up to 75% of patients with metastatic uveal melanoma often have multiple sites 
of involvement, primarily lung and bone.[12] Early detection allows early intervention. 
Although success of treatment is limited, surgical intervention, targeted hepatic 
chemotherapy, localized radiotherapy, small molecule kinase inhibitors and immune system 
modulators such as PD1 and MEK inhibitors are being now all being used in the management 
of patients with metastatic melanoma.[17,18] 
Second cancers 
Other extra-hepatic lesions found on PET/CT scanning included second primary malignancy 
in 9.3%. Early detection of a second asymptomatic primary cancer can improve patient 
survival.[18,19] Studies have found that detection of a second primary cancer following the 
diagnosis of an apparently unrelated cancer is not uncommon.[19,20,21,22] In fact, cancer patients 
have approximately twice the risk of the development of an additional primary cancer than 
cancer-free patients of the same sex and age.[23] In our series, whole-body PET/CT was able 
to provide early detection of asymptomatic, unrelated second primary cancers in almost 1 in 
10 patients with uveal melanoma. None of these patients reported symptoms that would have 
indicated a second primary cancer. Second primary cancers were found in the lung, breast, 
colon, thyroid and adrenal gland. The discovery of a second cancer was a somewhat 
unexpected, but important result. Hereditary BAP1 cancer predisposition syndrome provides 
a genetic explanation for the association of uveal melanoma with cutaneous melanoma, 
malignant pleural mesothelioma and renal cell carcinoma.[24] However, none of the second 
cancers found on our cohort were typical tumors seen in the described germline BAP1 
mutation. Nevertheless, this is a rapidly developing field; cholangiocarcinoma and breast 
cancer may also be part of the BAP1 phenotype.[24] Other candidate genes are likely to be 
involved in addition to BAP 1. This underscores the need to assess the whole patient 
following a diagnosis of uveal melanoma so that optimal patient care can be achieved in close 
collaboration with a medical oncologist. 
Imaging technique 
Performance of FDG-PET imaging is limited by numerous technical and methodological 
factors. First, it is more difficult to detect even metabolically active lesions if their size is <1 
cm. Second, FDG uptake reflects glucose metabolic flux, which is physiologically present in 
normal liver. Thus, the normal ''mottled'' background is another factor which decreases the 
sensitivity of liver lesion detection and the target to background ratio. Lesions that are quite 
large may not be detected if their metabolism matches that of the patient's liver. The last 
important limitation of PET/CT imaging is the respiratory motion that produces localization 
and reconstruction artefacts. Respiratory gating techniques, mainly used in chest pathologies, 
should possibly improve the results. Servois et al.[25] proved that MRI is superior to PET 
alone in a small preoperative case series of uveal melanoma patients with hepatic metastases. 
Yet, they focused on hepatic involvement. They acknowledged that PET, as whole-body 
imaging modality, presents the advantage of also detecting extrahepatic metastases. The 
limitations of PET scan alone such as, the partial volume effect, physiologically high 
intrahepatic glucose metabolism, and artifacts by respiratory motion can be largely overcome 
by using combined PET/CT scan and adequate breathing techniques.[16] 
Ultrasound is a noninvasive, simple to perform and a low cost technique, which provides 
detailed examination and in our series was superior to the PET/CT scan in detecting hepatic 
abnormalities and providing details of many other benign abnormalities. Ultrasound provides 
the immediate advantage of instant reporting. However, ultrasound technique is operator 
dependent and therefore the quality of the report can vary with the experience of the operator. 
In this study, ultrasound scans were performed by highly experienced radiologists our cancer 
institution. 
In Summary, the incidence of metastatic uveal melanoma at the time of primary diagnosis 
remains low even for larger tumors. Benign hepatic disease is common and best detected with 
abdominal ultrasound, which provides a baseline description of the liver architecture and is 
useful for future screening. Full-body PET/CT allows detection of extra-hepatic disease; we 
report a second cancers detection rate of 9.3%, which is highly relevant. Therefore, the dual 
imaging techniques complement each other in the early detection of metastatic disease and 
second malignancies in uveal melanoma. No cost benefit analysis was undertaken in this 
study and ultimately this might adversely affect the global uptake of PET/CT imaging for 
staging uveal melanoma. However, it is important to remember the high incidence of an 
asymptomatic, second primary malignancy in this group of patients. 
Conclusion 
Whole body PET/CT and abdominal ultrasound complement each other in the staging of 
uveal melanoma. Benign hepatic abnormalities found using ultrasound are common. A 
second asymptomatic primary malignancy was seen in almost 10% of patients with uveal 
melanoma. 
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Figures and Tables 
Figure 1 
 A coronal plane whole body (18) fluorodeoxyglucose positron emission tomography/computed 
tomography image. The highlighted arrow depicts extensive uptake in the liver consistent with a large 
metastatic tumour burden 
Table 1 
Patient demographics and tumor data 
 Figure 2 
 Comparison of imaging results for the same patient using liver ultrasound scan and a transverse plane (18) 
fluorodeoxyglucose positron emission tomography/computed tomography. The arrow indicates the 
location of a small isolated liver metastasis on ultrasound, which demonstrates fluorodeoxyglucose uptake 
on positron emission tomography/computed tomography 
 
